Bone Indices in Thyroidectomized Patients on Long-Term Substitution Therapy with Levothyroxine Assessed by DXA and HR-pQCT
Table 3
Characteristics of studied patients stratified by etiology of thyroid disease. Tests were performed by univariate ANOVA, adjusted for gender, age, and BMI. values are based on -tests. Mean values with 95% confidence intervals.
Nontoxic goiter ()
Toxic goiter ()
Thyroid cancer ()
value
Biochemistry
Dose of levothyroxine, µg/d†
107 (81–161)
136 (114–150)
171 (150–193)
0.07
TSH (103 IU/L)
2.69 (2.00–3.38)
2.44 (1.92–2.96)
1.72 (0.46–2.99)
0.44
T3 (nmol/L)
1.55 (1.45–1.66)
1.49 (1.41–1.57)
1.61 (1.42–1.80)
0.42
T4 (nmol/L)
103 (94–113)
111 (104–118)
112 (96–129)
0.41
T4-uptake
1.06 (1.02–1.09)
1.05 (1.02–1.07)
1.04 (0.98–1.10)
0.84
T4/T3 ratio
67.5 (60.5–74.5)
75.9 (70.7–81.2)
71.4 (58.6–84.2)
0.16
Creatinine (µmol/L)
73.8 (68.8–78.8)
68.5 (64.8–72.3)
78.0 (68.9–87.1)
0.08
eGFR (mL/min)
76 (71–81)
81 (77–85)
73 (64–82)
0.09
Calcium, ionized (mmol/L)
1.19 (1.17–1.21)
1.20 (1.19–1.22)
1.17 (1.13–1.20)
0.18
PTH (pmol/L)
3.69 (2.91–4.71)
4.27 (3.68–4.85)
3.36 (1.93–4.79)
0.32
25-Hydroxyvitamin D (nmol/L)
77.4 (66.3–88.4)c
69.7 (61.5–78.0)c
106.4 (86.3–126.5)
0.006
Bone structure (by HRpQCT scans), radius#
Total area (mm2)
316 (287–346)c
299 (277–321)
250 (198–303)a
0.10
Total bone density (mg HA/cm3)
306 (270–342)
307 (280–334)c
378 (315–442)b
0.06
Cortical Area (mm2)
54 (47–60)c
56 (51–61)
67 (56–79)a
0.10
Cortical thickness (mm)
0.74 (0.64–0.84)c
0.76 (0.69–0.84)c
0.98 (0.80–1.16)a,b
0.08
Kruskal-Wallis test, unadjusted. compared with patients with anontoxic goiter, btoxic goiter, and cthyroid cancer. and compared with the group of matched controls. #Only indices that differed significantly between groups are shown. No differences were found at the tibia.
